Sign in or Register   Sign in or Register
  |  

Mouse Anti-CDK7 Recombinant Antibody (8C67) (CBMAB-C2130-CN)

This product is a Mouse antibody that recognizes CDK7. The antibody 8C67 can be used for immunoassay techniques such as: FC, Dot, IF, IP, WB.
See all CDK7 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
8C67
Antibody Isotype
IgG1
Application
FC, Dot, IF, IP, WB

Basic Information

Immunogen
Partial recombinant protein corresponding to a portion of human cdk7
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, pH 7.4, 1% BSA
Preservative
0.05% Sodium azide
Concentration
0.1 mg/mL

Target

Full Name
Cyclin Dependent Kinase 7
Introduction
CDK7 (Cyclin Dependent Kinase 7) is a Protein Coding gene. Diseases associated with CDK7 include Breast Cancer and Hemophagocytic Lymphohistiocytosis, Familial, 3. Among its related pathways are RNA Polymerase II Transcription Initiation And Promoter Clearance and Formation of HIV elongation complex in the absence of HIV Tat. Gene Ontology (GO) annotations related to this gene include transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity. An important paralog of this gene is CDK20.
Entrez Gene ID
UniProt ID
Alternative Names
Cyclin Dependent Kinase 7; Cyclin-Dependent Kinase 7 (MO15 Homolog, Xenopus Laevis, Cdk-Activating Kinase); TFIIH Basal Transcription Factor Complex Kinase Subunit; Cell Division Protein Kinase 7; CDK-Activating Kinase 1; 39 KDa Protein Kinase; EC 2.7.11.22; CDKN7; STK1; CAK1; MO15; CAK; Cyclin-Dependent Kinase 7 (Homolog Of Xenopus MO15 Cdk-Activating Kinase); Homolog Of Xenopus MO15 Cdk-Activating Kinase;
Function
Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition.
Biological Process
7-methylguanosine mRNA capping Source: Reactome
Cell cycle arrest Source: UniProtKB
Cell division Source: UniProtKB-KW
G1/S transition of mitotic cell cycle Source: Reactome
G2/M transition of mitotic cell cycle Source: Reactome
Nucleotide-excision repair, preincision complex assembly Source: Reactome
Phosphorylation of RNA polymerase II C-terminal domain Source: GO_Central
Positive regulation of transcription by RNA polymerase II Source: GO_Central
Protein phosphorylation Source: GO_Central
Protein stabilization Source: CAFA
Regulation of cyclin-dependent protein serine/threonine kinase activity Source: ProtInc
snRNA transcription by RNA polymerase II Source: Reactome
Termination of RNA polymerase I transcription Source: Reactome
Transcription by RNA polymerase II Source: UniProtKB
Transcription-coupled nucleotide-excision repair Source: Reactome
Transcription elongation from RNA polymerase II promoter Source: Reactome
Transcription initiation from RNA polymerase II promoter Source: ARUK-UCL
Transcription initiation from RNA polymerase I promoter Source: Reactome
Cellular Location
Nucleus; Cytoplasm; Perinuclear region. Colocalizes with PRKCI in the cytoplasm and nucleus. Translocates from the nucleus to cytoplasm and perinuclear region in response to DNA-bound peptides.
PTM
Phosphorylation of Ser-164 during mitosis inactivates the enzyme. Phosphorylation of Thr-170 is required for activity. Phosphorylated at Ser-164 and Thr-170 by CDK2.

Ma, H., Dean, D. C., Wei, R., Hornicek, F. J., & Duan, Z. (2021). Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma. Therapeutic advances in musculoskeletal disease, 13, 1759720X21995069.

Lin, Y., Xue, K., Li, Q., Liu, Z., Zhu, Z., Chen, J., ... & Li, B. (2021). Cyclin-Dependent Kinase 7 Promotes Th17/Th1 Cell Differentiation in Psoriasis by Modulating Glycolytic Metabolism. Journal of Investigative Dermatology.

Miao, J., Kyoyama, H., Liu, L., Chan, G., Wang, Y., Urisman, A., ... & You, L. (2020). Inhibition of cyclin‐dependent kinase 7 down‐regulates yes‐associated protein expression in mesothelioma cells. Journal of cellular and molecular medicine, 24(1), 1087-1098.

Li, B. B., Wang, B., Zhu, C. M., Tang, D., Pang, J., Zhao, J., ... & Qian, Z. R. (2019). Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy. Chronic diseases and translational medicine, 5(3), 155-169.

Teng, Y., Lu, K., Zhang, Q., Zhao, L., Huang, Y., Ingarra, A. M., ... & Oumata, N. (2019). Recent advances in the development of cyclin-dependent kinase 7 inhibitors. European journal of medicinal chemistry, 183, 111641.

Shi, C. S., Kuo, K. L., Chen, M. S., Chow, P. M., Liu, S. H., Chang, Y. W., ... & Huang, K. H. (2019). Suppression of angiogenesis by targeting cyclin-dependent kinase 7 in human umbilical vein endothelial cells and renal cell carcinoma: an in vitro and in vivo study. Cells, 8(11), 1469.

Mbonye, U., Wang, B., Gokulrangan, G., Shi, W., Yang, S., & Karn, J. (2018). Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation. Journal of Biological Chemistry, 293(26), 10009-10025.

Huang, J. R., Qin, W. M., Wang, K., Fu, D. R., Zhang, W. J., Jiang, Q. W., ... & Shi, Z. (2018). Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo. American journal of translational research, 10(11), 3664.

Zhong, L., Yang, S., Jia, Y., & Lei, K. (2018). Inhibition of cyclin‐dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis. Journal of cellular biochemistry, 119(12), 9742-9751.

Gong, Y., Yang, J., Liu, F., Li, Z., Gong, R., & Wei, T. (2018). Cyclin-dependent kinase 7 is a potential therapeutic target in papillary thyroid carcinoma. Journal of biological regulators and homeostatic agents, 32(6), 1361-1368.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-CDK7 Recombinant Antibody (8C67)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare